Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pneumovax Vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Pneumovax Vaccine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-002789-12 Sponsor Protocol Number: U05-PnPS-403 Start Date*: 2005-09-28
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all curre...
    Medical condition: Prevention of invasive pneumococcal disease (IPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002657-30 Sponsor Protocol Number: WS2287576 Start Date*: 2012-09-12
    Sponsor Name:HYKS-instituutti
    Full Title: Immunogenicity of repeated dose 13-valent pneumococcal conjugate vaccine compared to the existing recommended protocol of pneumococcal polysaccharide vaccine in adult kidney and liver transplant pa...
    Medical condition: Immunogenicity of pneumococcal vaccines in liver and kidney transplant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000560-93 Sponsor Protocol Number: 106623 Start Date*: 2006-06-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal con...
    Medical condition: A single dose of Sanofi Pasteur MSD’s unconjugated 23-valent polysaccharide pneumococcal vaccine (Pneumovax™23) to healthy children who were previously primed with the full three doses of GSK Biolo...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003007-29 Sponsor Protocol Number: 2014-0087054 Start Date*: 2015-08-12
    Sponsor Name:University Hospitals Leuven, department of pediatrics
    Full Title: The Polysaccharide Antibody Response Study: Typhim Vi response and allohemagglutinins versus Pneumo 23 vaccine response in the diagnosis of Specific Polysaccharide Antibody Deficiency.
    Medical condition: Specific polysaccharide antibody deficiency.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003052-36 Sponsor Protocol Number: 105555 Start Date*: 2005-11-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of...
    Medical condition: Booster vaccination against Streptococcus pneumoniae in healthy children having previously received vaccines as a primary 3-dose vaccination course in the study 11PN-PD-DIT-002.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000344-26 Sponsor Protocol Number: V211-012-00 Start Date*: 2007-06-04
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s...
    Medical condition: herpes zoster, pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-018596-24 Sponsor Protocol Number: 6311 Start Date*: 2011-05-19
    Sponsor Name:Oxford Radcliffe Hospital NHS Trust
    Full Title: Assessment of Salmonella Typhim Vi(TM) vaccine (Sanofi Pasteur MSD) for the investigation of selective antibody deficiency to polysaccharide.
    Medical condition: Suspected primary antibody deficiency states will be investigated
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004013-85 Sponsor Protocol Number: ZKSJ0073 Start Date*: 2016-03-21
    Sponsor Name:Friedrich Schiller University Jena
    Full Title: Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibod...
    Medical condition: previously unvaccinated older healthy adults
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069578 Pneumococcal immunisation PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005314-19 Sponsor Protocol Number: 116889 Start Date*: 2014-01-30
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23 ...
    Medical condition: Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults ≥ 50 years of age [YOA ] and immunocompromised adults ≥ 18 YOA.)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    17.0 10021881 - Infections and infestations 10019972 Herpes viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004024-30 Sponsor Protocol Number: V114-016 Start Date*: 2018-08-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Y...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023313-57 Sponsor Protocol Number: INF Start Date*: 2012-04-10
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Homing potential of the antigen specific B cell and antibody mediated immune response after vaccination
    Medical condition: Basic healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003620-16 Sponsor Protocol Number: IIV-465 Start Date*: 2021-05-27
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Vaccine immunogenicity in Dutch frail versus non-frail older individuals (participating in the Doetinchem Cohort study)
    Medical condition: Older adults 73-79 years of age, birth cohorts year 1941-1947, still participating in round 6 of the Doetinchem Cohort Study.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-007605-37 Sponsor Protocol Number: 112807 Start Date*: 2009-05-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar...
    Medical condition: A single dose of either 10Pn-PD-DiT or Prevenar vaccine to healthy children previously primed with 3 primary doses of 10Pn-PD-DiT or Prevenar vaccine in study 10PN-PD-DIT-003 (105554) and a booster...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004542-18 Sponsor Protocol Number: V114-002 Start Date*: 2012-04-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and ...
    Medical condition: prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 1, 5, 7F, 3, 6A, 19A, 22F,...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035728 Pneumonia pneumococcal PT
    14.1 10021881 - Infections and infestations 10054047 Pneumococcal sepsis PT
    14.1 10021881 - Infections and infestations 10058886 Pneumococcal bacteremia LLT
    14.1 10021881 - Infections and infestations 10027253 Meningitis pneumococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003761-16 Sponsor Protocol Number: 9818P Start Date*: 2005-11-24
    Sponsor Name:Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust
    Full Title: Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia
    Medical condition: Pneumococcal disease is a common form of meningitis, septicaemia and pneumonia. Those individuals at highest risk include children, the elderly and persons whose immune systems are impaired. This l...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001656-29 Sponsor Protocol Number: V110-018 Start Date*: 2015-04-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal D...
    Medical condition: Vaccination against pneumococcal disease caused by the 23 serotypes included in the vaccine
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001909-32 Sponsor Protocol Number: V114-018 Start Date*: 2018-07-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eigh...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000260-99 Sponsor Protocol Number: 10102010 Start Date*: 2011-04-12
    Sponsor Name:Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8
    Full Title: Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial
    Medical condition: The primary objectives of this study are to: 1. Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one y...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001299-79 Sponsor Protocol Number: IMVX2014 Start Date*: 2014-10-06
    Sponsor Name:Department of Infectious Diseases, Odense University Hospital
    Full Title: Pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy
    Medical condition: Immunoresponse on pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10069594 Pneumococcal immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004123-23 Sponsor Protocol Number: Immunovax_Renal Start Date*: 2017-04-20
    Sponsor Name:Department of Infectious Diseases, Odense University Hospital
    Full Title: Immunization of immunosuppressed patients – Knowledge, practices and serological response
    Medical condition: Immunoresponse on pneumococcal vaccination of kidney transplant recipients in immunomodulatory therapy or patients with end stage renal disease.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    21.1 100000004865 10069594 Pneumococcal immunization LLT
    20.0 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:38:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA